These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19744089)

  • 1. Long-term results after conversion from calcineurin inhibitors to sirolimus in renal transplant patients.
    Martinez-Mier G; Avila-Pardo SF; Mendez-Lopez MT; Budar-Fernandez LF
    Clin Transplant; 2010; 24(4):467-73. PubMed ID: 19744089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion to sirolimus in renal transplant recipients: a single-center experience.
    Yelken B; Caliskan Y; Ozkan O; Gorgulu N; Yazici H; Turkmen A; Sever MS
    Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion to sirolimus for chronic allograft dysfunction: long-term results confirm predictive value of proteinuria.
    Diekmann F; Budde K; Slowinski T; Oppenheimer F; Fritsche L; Neumayer HH; Campistol JM
    Transpl Int; 2008 Feb; 21(2):152-5. PubMed ID: 18005087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
    Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
    Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from calcineurin inhibitors to sirolimus in kidney transplant recipients: a retrospective cohort study.
    Cardinal H; Froidure A; Dandavino R; Daloze P; Hébert MJ; Colette S; Boucher A
    Transplant Proc; 2009 Oct; 41(8):3308-10. PubMed ID: 19857737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion from sirolimus to everolimus in kidney transplant recipients receiving a calcineurin-free regimen.
    Carvalho C; Coentrão L; Bustorff M; Patrício E; Sampaio S; Santos J; Oliveira G; Pestana M
    Clin Transplant; 2011; 25(4):E401-5. PubMed ID: 21457330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients.
    Rogers CC; Johnson SR; Mandelbrot DA; Pavlakis M; Horwedel T; Karp SJ; Egbuna O; Rodrigue JR; Chudzinski RE; Goldfarb-Rumyantzev AS; Hanto DW; Curry MP
    Clin Transplant; 2009; 23(6):887-96. PubMed ID: 19681971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of glomerular filtration rate, renal injury markers, anemia, and angiotensin blockers use after change from calcineurin inhibitors to sirolimus in transplant patients with neoplasia versus chronic allograft nephropathy.
    Luna E; Cerezo I; Macias R; Villa J; Martinez C; Cubero J; Martinez R; Ferreira F; García C
    Transplant Proc; 2011; 43(6):2187-90. PubMed ID: 21839229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
    Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus as primary immunosuppression in kidney transplantation: experience in conversion from calcineurin inhibitors.
    Sánchez-Fructuoso AI; Ruiz JC; Calvo N; Rodrigo E; Perez-Flores I; Gómez-Alamillo C; Fernández-Pérez C; Arias M; Barrientos A
    Transplantation; 2012 Feb; 93(4):398-405. PubMed ID: 22245871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation.
    Hunt J; Lerman M; Magee MJ; Dewey TM; Herbert M; Mack MJ
    J Heart Lung Transplant; 2005 Nov; 24(11):1863-7. PubMed ID: 16297793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
    Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
    Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: a multicenter study.
    Ruiz JC; Diekmann F; Campistol JM; Sanchez-Fructuoso A; Rivera C; Oliver J; Fernandez-Fresnedo G; Arias M
    Transplant Proc; 2005 Nov; 37(9):3833-5. PubMed ID: 16386555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.